This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Lucinda Osborne
Lucinda Osborne
London +44 20 7067 2030 Download V-card

Lucinda Osborne specializes in technology transactions in the life science sector with a particular emphasis on complex strategic collaborations as well as technology and product transfers and licensing arrangements in the context of mergers and acquisitions.

Chambers UK (2015) states that Ms. Osborne “has devoted her career to life sciences collaboration and licence agreements” and notes that “[o]ne key client said: ‘She is great - she always delivers, the client care is fantastic, and she gives really pragmatic, speedy and good advice.’”

  • AstraZeneca in its:
    • strategic collaboration with Isis Pharmaceuticals, Inc. to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases for an upfront fee of $65 million, development and regulatory milestones for each programme that AstraZeneca advances to clinical development, and tiered double-digit royalties on annual net sales;
    • licensing agreement with Heptares Therapeutics under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds, involving an upfront payment of $10 million, potential milestone payments of more than $500 million subject to successful completion of development and commercialisation milestones, and up to double-digit tiered royalties on net sales;
    • acquisition of the rights to Actavis' branded respiratory business in the U.S. and Canada for an initial consideration of $600 million on completion;
    • agreement to transfer to the company the rights to Almirall’s respiratory franchise for $875 million on completion and up to $1.22 billion in development, launch, and sales-related milestones;
    • acquisition of Bristol-Myers Squibb's interests in the companies’ diabetes alliance for $2.7 billion on completion and up to $1.4 billion in regulatory, launch and sales-related payments; and
    • agreement with Moderna Therapeutics to develop and commercialize messenger RNA therapeutics for the treatment of cardiovascular, metabolic, and renal diseases, as well as cancer, which involved an upfront payment of $240 million and up to $180 million in technical milestones.
  • UCB in its:
    • world-wide collaboration with Neuropore Therapies Inc. to develop and commercialize therapeutic products aiming at slowing the progression of Parkinson’s disease and related disorders; and
    • collaboration with Vectura Group plc for the development of an innovative biologic immunomodulatory product in the area of severe inflammatory respiratory disease.
  • Advising Illumina on its strategic alliance agreement with Genomics England in respect of sequencing genomes of patients with cancer and rare diseases, as part of a four-year UK government project to decode 100,000 human genomes by 2017.  
  • Represented MedImmune, the global biologics research and development arm of AstraZeneca, on a collaboration agreement with ADC Therapeutics to jointly develop two of ADC Therapeutics’ antibody-drug conjugate programmes in preclinical development.
  • Advised Vernalis plc in connection with a license agreement with Tris Pharma, Inc to develop up to six novel formulations of existing products sold in the US prescription cough/cold market.
  • Represented Emergent BioSolutions, on a variety of strategic transactions in Europe including the creation of its joint venture and related licensing and commercial arrangements with the University of Oxford and its technology transfer office, Isis Innovation Limited, to further develop MVA85A, thought to be the world’s most clinically advanced vaccine candidate for the prevention of tuberculosis.
  • Advised Boehringer Ingelheim Vetmedica Inc. in its acquisition of certain animal health products divested by Wyeth and Pfizer Inc. pursuant to an FTC consent order entered into in connection with Pfizer Inc.’s acquisition of Wyeth.
  • Represented Intercell AG in connection with its acquisition of Cytos Biotechnology Ltd’s platform technology for monoclonal antibody discovery.
  • Represented Amyris, Inc. which operates an industrial synthetic biology platform, in a partnership with Total, an international oil and gas company, to develop products under a wide-spectrum master development and collaboration agreement.
  • Represented Novartis Vaccines and Diagnostics (formerly Chiron) in a wide variety of transactions and commercial matters, including its spin-off of its powder injection DNA vaccine technology and related development programs, licenses and strategic transactions, distribution and manufacturing arrangements, tender documents, and outsourcing.
  • Chambers UK, Life Sciences and Life Sciences: Transactional (2015-2016)
  • LMG Life Sciences Europe, Life Sciences Star - Financial & Transactional (United Kingdom) (2014-2015)
  • Euromoney Legal Media Group, Europe Women in Business Law Awards - Winner for Life Sciences (2015); shortlisted for Life Sciences (2016)  
  • IAM Patent 1000 - The World’s Leading Patent Practitioners (2012-2016)
  • Legal 500 UK, Pharmaceuticals and Biotechnology (2010-2016) and Commercial Contracts (2014-2015)
  • Super Lawyers - London, Business Affairs (2013)
  • PLC’s Life Sciences, Which Lawyer?, Commercial & Partnering (2006-2012)